OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.520
-0.150 (-8.98%)
At close: Aug 31, 2026, 4:00 PM EDT
1.510
-0.010 (-0.66%)
After-hours: Aug 31, 2026, 7:30 PM EDT
Company Description
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom.
Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited
| Country | United Kingdom |
| Founded | 2007 |
| IPO Date | May 17, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Robert Dempsey |
Contact Details
Address: 35a Albemarle St, Floor 2 London, W1S 4JE United Kingdom | |
| Phone | 44 20 7495 2379 |
| Website | okyopharma.com |
Stock Details
| Ticker Symbol | OKYO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 1849296 |
| CUSIP Number | 679345108 |
| ISIN Number | GG00BMFG5F62 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert J. Dempsey M.B.A. | Chief Executive Officer and Executive Director |
| Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
| Dr. Gary S. Jacob Ph.D. | Chief Development Officer and Director |
| Dr. Flavio Mantelli M.D., Ph.D. | Chief Medical Officer |
| Michael Paul Beck | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2026 | 20-F/A | Filing |
| Jul 28, 2026 | 6-K | Report of foreign issuer |
| Jul 27, 2026 | 6-K | Report of foreign issuer |
| Jul 23, 2026 | 6-K | Report of foreign issuer |
| Jul 23, 2026 | 6-K | Report of foreign issuer |
| Jul 22, 2026 | 6-K | Report of foreign issuer |
| Jul 22, 2026 | 6-K | Report of foreign issuer |
| Jul 22, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 6-K | Report of foreign issuer |
| Jul 21, 2026 | 6-K | Report of foreign issuer |